Nuo and Nord: Former Pfizer research and development department manager will not run for company board member.

Novo Nordisk announced on November 13th that Mikael Dolsten will not run for the board of directors, a decision that contradicts the statement in the previous shareholder meeting notice. Mikael Dolsten, who previously served as the head of research and development at Pfizer, informed Novo Nordisk today that despite his desire to join the board, he has decided to withdraw his candidacy as a director and observer due to personal reasons unrelated to Novo Nordisk.